Support teaching, research, and patient care.
The use of molecular and molecular cytogenetic methods to identify chromosomal abnormalities in acquired and congenital disorders.
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
The primary objective of this study was to evaluate the safety and efficacy of the
combination of fludarabine and cyclophosphamide in previously untreated CLL patients.
Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day
Stanford is currently not accepting patients for this trial.
For more information, please contact Nini Estevez, 6507254041.
View full details